Indoco Remedies: Please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in…

What happened

Indoco Remedies (INDOCO) filed a disclosure with the exchanges on 28 September 2026 at 08:58 PM titled "Please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in the name and style".

Company snapshot

Indoco Remedies is a small-cap company, with a market value of about ₹2,349 crore.

The stock last traded at ₹254.5, against a 52-week range of ₹162.2–₹317.4 (19.8% below the high).

Before this filing the shares had moved +4.9% over the month and +6.4% over three months. Average daily turnover over the last 20 sessions was about ₹47.34 crore.

Promoters held 58.86% at the end of Q1 FY27. Foreign institutions owned 1.27% and domestic institutions 17.68%.

What history shows

This is not the company's first m&a disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Market-wide, 1,921 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Regulatory approvals, completion of the deal and its effect on revenue and margins.

In the news

Recent coverage elsewhere (links open the original publisher):

• Indoco Remedies (INDOCO.NS) Climbs 3.21% to ₹257.01, Nears Key Resistance Zone - Imbalance Zone — siam.in, 21 Sept 2026
• Indoco Remedies Share Price Drops; Technicals in Focus — Univest, 15 Sept 2026
• Indoco Remedies approves incorporation of Warren Lifesciences subsidiary — scanx.trade, 18 Sept 2026
• Indoco Remedies (INDOCO.NS) Slips 8.22% to ₹241.39 as Stock Tests Key Support Zone - Ending Diagonal — siam.in, 16 Sept 2026
• Zydus Lifesciences vs IOL Chemicals and Pharmaceuticals vs Indoco Remedies: Which Stock Should You Track — Univest, 25 Sept 2026

Source

• Exchange filing (PDF)